[{"id":"6be16700-40fa-4a2b-9c83-3b52bad7278e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04134312","created_at":"2021-01-18T20:11:50.267Z","updated_at":"2024-07-02T16:36:27.931Z","phase":"Phase 1","brief_title":"A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer","source_id_and_acronym":"NCT04134312","lead_sponsor":"Bavarian Nordic","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" ALK fusion • RAS mutation • ER positive + PGR positive • PGR positive","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • RAS mutation • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MVA-BN-Brachyury IV vaccine"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/08/2020","start_date":" 01/08/2020","primary_txt":" Primary completion: 01/12/2021","primary_completion_date":" 01/12/2021","study_txt":" Completion: 04/06/2021","study_completion_date":" 04/06/2021","last_update_posted":"2021-07-14"}]